On July 24, 2019, the World Bank announced that it had debarred a business unit of Merck Sharp & Dohme B.V. (MSD B.V.), a Dutch subsidiary of the U.S. publicly traded pharmaceutical company Merck & Co. According to the facts of the case, the MSD B.V. business unit, which successfully bid on a contract to supply contraceptives for a health systems improvement project in Bangladesh, failed to disclose the full commission amount its predecessor company had agreed to pay its local agent. The debarment is for a reduced period of twelve months as a result of MSD B.V.’s cooperation and voluntary remedial actions.
July 24, 2019
World Bank imposes 12-month debarment for fraudulent practices in connection with a Bangladeshi health development program
Related by Topic
New Post
Florida judge sentences reinsurance manager to 10 months’ time served for role in Ecuadorian bribery scheme
July 2, 2025
News Alert
New Post
Rising Cross-Border Enforcement Risk for Companies Operating in Latin America
June 26, 2025
Insight